References
1. Gnacińska M, Małgorzewicz S, Stojek M, Łysiak-Szydłowska W, Sworczak
K. Adv Med Sci Role of adipokines in complications related to obesity: a
review. 2009 (54):150-7.
2. Iannone F, Fanizzi R, Notarnicola A, Scioscia C, Anelli MG, Lapadula
G. Joint Bone Spine Obesity reduces the drug survival of second line
biological drugs following a first TNF-α inhibitor in rheumatoid
arthritis patients. 2015 (82):187-91.
3. Iannone F, Lopalco G, Rigante D, Orlando I, Cantarini L, Lapadula G.
Autoimmun Rev Impact of obesity on the clinical outcome of rheumatologic
patients in biotherapy. 2016 (15):447-50.
4. Budulgan M, Dilek B, Dağ ŞB, Batmaz I, Yıldız İ, Sarıyıldız MA,et al. . Clin Rheumatol Relationship between serum leptin level
and disease activity in patients with systemic sclerosis. 2014
(33):335-9.
5. Winsz-Szczotka K, Kuźnik-Trocha K, Komosińska-Vassev K, Kucharz E,
Kotulska A, Olczyk K. Int J Rheum Dis Relationship between adiponectin,
leptin, IGF-1 and total lipid peroxides plasma concentrations in
patients with systemic sclerosis: possible role in disease development.
2016 (19):706-14.
6. Pehlivan Y, Onat AM, Ceylan N, Turkbeyler IH, Buyukhatipoglu H, Comez
G, et al. . Int J Rheum Dis Serum leptin, resistin and TNF-α
levels in patients with systemic sclerosis: the role of adipokines in
scleroderma. 2012 (15):374-9.
7. Korman BD, Marangoni RG, Hinchcliff M, Shah SJ, Carns M, Hoffmann A,et al. . Arthritis Rheumatol Brief Report: Association of Elevated
Adipsin Levels With Pulmonary Arterial Hypertension in Systemic
Sclerosis. 2017 (69):2062-8.
8. Michalska-Jakubus M, Sawicka K, Potembska E, Kowal M, Krasowska D.
Postepy Dermatol Alergol Clinical associations of serum leptin and
leptin/adiponectin ratio in systemic sclerosis. 2019 (36):325-38.
9. Tomčík M, Arima K, Hulejová H, Kuklová M, Filková M, Braun M,et al. . Cytokine Adiponectin relation to skin changes and
dyslipidemia in systemic sclerosis. 2012 (58):165-8.
10. Żółkiewicz J, Stochmal A, Rudnicka L. Arch Dermatol Res The role of
adipokines in systemic sclerosis: a missing link? 2019 (311):251-63.
11. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall
A, et al. . Arthritis Rheum 2013 classification criteria for
systemic sclerosis: an American College of Rheumatology/European League
against Rheumatism collaborative initiative. 2013 (65):2737-47.
12. Furst DE, Clements PJ, Steen VD, Medsger TA, Masi AT, D’Angelo WA,et al. . J Rheumatol The modified Rodnan skin score is an accurate
reflection of skin biopsy thickness in systemic sclerosis. 1998
(25):84-8.
13. LeRoy EC, Medsger TA. J Rheumatol Criteria for the classification of
early systemic sclerosis. 2001 (28):1573-6.
14. Cutolo M, Matucci Cerinic M. Clin Exp Rheumatol Nailfold
capillaroscopy and classification criteria for systemic sclerosis. 2007
(25):663-5.
15. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ,
D’Angelo S, et al. . Ann Rheum Dis European multicentre study to
define disease activity criteria for systemic sclerosis. II.
Identification of disease activity variables and development of
preliminary activity indexes. 2001 (60):592-8.
16. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, et
al. . Arthritis Rheum Increased interleukin-17 production in patients
with systemic sclerosis. 2000 (43):2455-63.
17. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F,et al. . Clin Exp Immunol Cytokine and chemokine levels in
systemic sclerosis: relationship with cutaneous and internal organ
involvement. 2004 (138):540-6.
18. Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, et
al. . Arthritis Res Ther Plasma cytokine profiles in systemic sclerosis:
associations with autoantibody subsets and clinical manifestations. 2009
(11):R147.
19. Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato
S. Clin Rheumatol Serum chemokine and cytokine levels as indicators of
disease activity in patients with systemic sclerosis. 2011 (30):231-7.
20. Arakawa H, Jinnin M, Muchemwa FC, Makino T, Kajihara I, Makino K,et al. . Exp Dermatol Adiponectin expression is decreased in the
involved skin and sera of diffuse cutaneous scleroderma patients. 2011
(20):764-6.
21. Lakota K, Wei J, Carns M, Hinchcliff M, Lee J, Whitfield ML,et al. . Arthritis Res Ther Levels of adiponectin, a marker for
PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis:
potential utility as biomarker? 2012 (14):R102. doi: 10.1186/ar3827.
22. Masui Y, Asano Y, Shibata S, Noda S, Akamata K, Aozasa N, et
al. . Rheumatology (Oxford) A possible contribution of visfatin to the
resolution of skin sclerosis in patients with diffuse cutaneous systemic
sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and
Th1 polarization of the immune response. 2013 (52):1239-44.
23. Masui Y, Asano Y, Akamata K, Aozasa N, Noda S, Taniguchi T, et
al. . Rheumatol Int Serum resistin levels: a possible correlation with
pulmonary vascular involvement in patients with systemic sclerosis. 2014
(34):1165-70.
24. Neumann E, Lepper N, Vasile M, Riccieri V, Peters M, Meier F,et al. . Cytokine Adipokine expression in systemic sclerosis lung
and gastrointestinal organ involvement. 2019 (117):41-9.
25. Kotulska A, Kucharz EJ, Brzezińska-Wcisło L, Wadas U. Clin Rheumatol
A decreased serum leptin level in patients with systemic sclerosis. 2001
(20):300-2.
26. Huertas A, Tu L, Gambaryan N, Girerd B, Perros F, Montani D,et al. . Eur Respir J Leptin and regulatory T-lymphocytes in
idiopathic pulmonary arterial hypertension. 2012 (40):895-904.
27. Komai AM, Brännmark C, Musovic S, Olofsson CS. J Physiol
PKA-independent cAMP stimulation of white adipocyte exocytosis and
adipokine secretion: modulations by Ca2+ and ATP. 2014 (592):5169-86.
28. Tilg H, Moschen AR. Clin Sci (Lond) Role of adiponectin and
PBEF/visfatin as regulators of inflammation: involvement in
obesity-associated diseases. 2008 (114):275-88.
29. Masui Y, Asano Y, Shibata S, Noda S, Aozasa N, Akamata K, et
al. . J Eur Acad Dermatol Venereol Serum adiponectin levels inversely
correlate with the activity of progressive skin sclerosis in patients
with diffuse cutaneous systemic sclerosis. 2012 (26):354-60.
30. Zapata-Gonzalez F, Auguet T, Aragonès G, Guiu-Jurado E, Berlanga A,
Martinez S, et al. . Int J Mol Sci Interleukin-17A Gene Expression
in Morbidly Obese Women. 2015 (16):17469-81.
31. Dorneles GP, Haddad DO, Fagundes VO, Vargas BK, Kloecker A, Romão
PR, et al. . Cytokine High intensity interval exercise decreases
IL-8 and enhances the immunomodulatory cytokine interleukin-10 in lean
and overweight-obese individuals. 2016 (77):1-9.
32. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. J Rheumatol Elevated
serum tumor necrosis factor-alpha levels in patients with systemic
sclerosis: association with pulmonary fibrosis. 1997 (24):663-5.
33. Distler JH, Jordan S, Airo P, Alegre-Sancho JJ, Allanore Y, Balbir
Gurman A, et al. . Clin Exp Rheumatol Is there a role for TNFα
antagonists in the treatment of SSc? EUSTAR expert consensus development
using the Delphi technique. 2011 (29):S40-5.
34. Bishop V, Harrison E, Lal S, Herrick AL. Scand J Rheumatol Evidence
for a clinical association between body mass index and malabsorption in
patients with systemic sclerosis. 2015 (44):341-3.
35. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J,et al. . Nature Identity of tumour necrosis factor and the
macrophage-secreted factor cachectin. 1985 (316):552-4.
36. Mahony SM, Beck SA, Tisdale MJ. Br J Cancer Comparison of weight
loss induced by recombinant tumour necrosis factor with that produced by
a cachexia-inducing tumour. 1988 (57):385-9.
37. Chen CY, Tsai CY, Lee PC, Lee SD. Curr Pharm Des Long-term
etanercept therapy favors weight gain and ameliorates cachexia in
rheumatoid arthritis patients: roles of gut hormones and leptin. 2013
(19):1956-64.
Table 1. Clinical findings of Systemic Sclerosis (SSc) cohort (n. 89
patients).